The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study
Value in Health · 2024
DOI: 10.1016/j.jval.2024.07.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2024. Verfasst von Valérie van Hezik-Wester und 8 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, …. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Quality-Adjusted Life Years, Quality of Life, Drug Resistant Epilepsy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Netherlands Organization for Health Research and Development, Ministerie van Volksgezondheid, Welzijn en Sport, ZonMw.
Abstract (Originalsprache)
OBJECTIVES: The Epilepsy Support Dog Evaluation study was commissioned by the Dutch Ministry of Health, Welfare and Sports to inform a reimbursement decision on seizure dogs. The randomized trial found that seizure dogs reduce seizure frequency and improve health-related quality of life of persons with severe refractory epilepsy (PSREs). This article examined the cost-effectiveness (CE) of adding seizure dogs to usual care for PSREs in The Netherlands. METHODS: A microsimulation model was developed, informed by generalized linear mixed models using patient-level trial data from the Epilepsy Support Dog Evaluation study. The model adopted a 10-year time horizon and took a societal perspective. Seizure frequency was predicted as a function of time with the seizure dog. Patient utilities, caregiver utilities, and costs were predicted as a function of seizure frequency and time with the seizure dog. RESULTS: Quality-adjusted life-years (QALYs) of PSREs with a seizure dog and usual care alone were estimated at 6.28 and 5.65, respectively (Δ 0.63). For caregivers, estimated QALYs were 6.94 and 6.52, respectively (Δ 0.42). Total costs were respectively €228 691 and €226 261 (Δ €2430). Intervention costs were largely offset by savings in informal care and healthcare. The incremental CE ratio was €2314/QALY. Probabilistic sensitivity analysis indicated a 91% probability of seizure dogs being cost-effective at the €50 000/QALY threshold. The incremental CE ratio fell well below this threshold in scenario analyses. CONCLUSIONS: Seizure dogs are likely to be a cost-effective addition to usual care for PSREs in The Netherlands.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Erasmus Cent…
- Academic Center for Epileptology, Kempenhaeghe, Heeze, The Netherlands.
- Stichting Epilepsie Instellingen Nederland, Heemstede, The Netherlands.
Förderung
- The Netherlands Organization for Health Research and Development
- Ministerie van Volksgezondheid, Welzijn en Sport
- ZonMw
Zitieren
APA
van Hezik-Wester, V., de Groot, S., Kanters, T., Wagner, L., Ardesch, J., Brouwer, W., Corro-Ramos, I., van Exel, J., & Versteegh, M. (2024). The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study. Value in Health. https://doi.org/10.1016/j.jval.2024.07.020
Vancouver
van Hezik-Wester V, de Groot S, Kanters T, Wagner L, Ardesch J, Brouwer W, et al. The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study. Value in Health. 2024. doi:10.1016/j.jval.2024.07.020
BibTeX
@article{vanHezikWester2024,
author = {van Hezik-Wester, Valérie and de Groot, Saskia and Kanters, Tim and Wagner, Louis and Ardesch, Jacqueline and Brouwer, Werner and Corro-Ramos, Isaac and van Exel, Job and Versteegh, Matthijs},
title = {The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study},
journal = {Value in Health},
year = {2024},
doi = {10.1016/j.jval.2024.07.020}
}
EUVIMED